HUM Humana
A Medicare Advantage giant in a margin trough; the price already assumes a partial recovery, so there is little cushion.
The story
Humana is the second-largest Medicare Advantage insurer, with a CenterWell primary care, pharmacy and home health platform that gives it real scale and some integration advantages in a growing senior market. Since 2023, rising medical utilization, V28 risk-adjustment cuts and star-rating losses have pushed operating margins from 4.3% to about 1.6%. It is a mature, scaled business in a cyclical trough, and what it is worth depends on whether MA pricing discipline and star recovery bring margins back to normal levels.
Senior demographics, the 2026 benefit repricing and modest membership gains support high-single-digit growth that fades to 3.5%. Margins recover over five years to about 3.7%, near the long-run managed-care average of 4-5% but discounted for permanently tighter MA risk adjustment and Humana's concentration in government programs. The insurer's light capital needs support a sales-to-capital ratio of about 4.5, and beta sits slightly above the 0.9 industry anchor because of policy exposure. Margins staying at today's 1.6% would justify the baseline value of about $107 instead of the current price.
Value drivers
| Revenue growth (Y1) | 8.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 8y |
| Target operating margin | 3.7% |
| Years to target margin | 5 |
| Sales-to-capital | 4.50 |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.7% |
| Terminal WACC | 8.9% |
Valuation bridge
| PV of explicit FCFF | 15.08B |
| PV of terminal value | 42.27B |
| Equity value | 48.12B |
| ÷ shares → per share | $400.76 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 157.33B | 8.0% | 2.0% | 2.70B | 2.59B | 108.61M | 99.92M |
| 2 | 168.91B | 7.4% | 2.5% | 3.48B | 2.57B | 911.68M | 771.58M |
| 3 | 180.25B | 6.7% | 2.9% | 4.34B | 2.52B | 1.82B | 1.42B |
| 4 | 191.19B | 6.1% | 3.3% | 5.27B | 2.43B | 2.84B | 2.03B |
| 5 | 201.57B | 5.4% | 3.7% | 6.26B | 2.31B | 3.95B | 2.60B |
| 6 | 211.22B | 4.8% | 3.7% | 6.56B | 2.14B | 4.41B | 2.68B |
| 7 | 219.97B | 4.1% | 3.7% | 6.83B | 1.94B | 4.89B | 2.72B |
| 8 | 227.67B | 3.5% | 3.7% | 7.07B | 1.71B | 5.36B | 2.75B |
Key risks
- Medical cost trends keep outrunning pricing, so margins stay stuck near 2%
- Star-rating downgrades and CMS rate notices or V28 risk-adjustment changes cut payments
- Political or regulatory moves against Medicare Advantage overpayment and coding intensity
Catalysts
- Star ratings recover for 2027 payments, restoring bonus revenue
- Favorable 2027 CMS final rate notice plus margin-first bid discipline showing up in EPS